Compare JELD & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JELD | YARW |
|---|---|---|
| Founded | 1960 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.7M | 154.5M |
| IPO Year | 2016 | 2017 |
| Metric | JELD | YARW |
|---|---|---|
| Price | $0.84 | $16.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $1.23 | ★ $57.33 |
| AVG Volume (30 Days) | ★ 1.2M | 175.0K |
| Earning Date | 11-03-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,211,181,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.14 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.93 | $12.39 |
| 52 Week High | $3.27 | $44.28 |
| Indicator | JELD | YARW |
|---|---|---|
| Relative Strength Index (RSI) | 28.94 | 39.97 |
| Support Level | N/A | $12.39 |
| Resistance Level | $1.48 | $20.57 |
| Average True Range (ATR) | 0.15 | 2.67 |
| MACD | -0.01 | 0.30 |
| Stochastic Oscillator | 1.56 | 38.90 |
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.